Program
Minoxidil
Also written as “Minoxidil Tablets”, “minoxidil + finasteride” and “5% minoxidil foam”.
Its studies are mostly in Alopecia · Hypotrichosis, led by 9 companies.
Drug pageMinoxidil: every studyMany companies study it; this page follows only the 13 they lead. All 40 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aneira Pharmaits history only | 21 open or running | phase 1since May 8, 2023 | Mar 17, 2023 | none ahead |
| Galderma Groupits history only | 20 open or running | no phasesince May 29, 2015 | May 29, 2015 | none ahead |
| Industrial Farmacéutica Cantabriaits history only | 21 open or running | phase 3since May 25, 2023 | May 25, 2023 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| 3SBioits history only | 10 open or running | phase 3since Jul 15, 2025 | Jul 15, 2025 | none ahead |
| Beijing Dayspring Pharmaceutical Technologyits history only | 10 open or running | phase 2since Jul 1, 2025 | Jul 1, 2025 | none ahead |
| Eurofarma Laboratoriosits history only | 11 open or running | phase 3since Apr 8, 2026 | Apr 8, 2026 | Oct 30, 2028phase 3 · NCT07529977 |
| Maja Kovacevic, MDits history only | 10 open or running | no phasesince Jun 25, 2015 | Jun 25, 2015 | none ahead |
| Samson Clinical Operations Pty | 10 open or running | phase 3since Apr 6, 2025 | Apr 6, 2025 | none ahead |
Also a collaborator on its studies: Bioskin and Astrum CRO, S.L.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Samson Clinical Operations Pty only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2025First study: phase 3 study in AlopeciaFirst studyNCT06924632 · 142 enrolled · Australia
TargetBeta
“Sulfonylurea receptor 2, Kir6.2 opener”ChEMBL 37, by rule
Studies
The one study Samson Clinical Operations Pty leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06924632Alopecia · Australia | 3 | Completed | May 15, 2026 | 142 |
How it is read
Names in the registry
- “Minoxidil Tablets”, 2 entries
- “Minoxidil”, 2 entries
- “minoxidil + finasteride”, 2 entries
- “5% minoxidil foam”, 1 entry
- “Minoxidil oral solution”, 1 entry
Conditions, from the studies’ own filings
- Alopecia, 11 studies
- Hypotrichosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.